-
Severe economic losses in global pig production.
- Important reduction in performance.
- Complex interaction with other pathogens (P.
multocida, A. pleuropneumoniae, H. parasuis, S. suis,
PRRSV, Swine Influenza Virus (SIV), type 2 of Porcine
Circovirus, etc.): Porcine Respiratory Disease Complex
(PRDC)
- 30-95% of slaughtered pigs may show typical lesions.
- Up to 60-99% herds may be positive to M. hyopneumoniae.
|
1.
Carbomer: long-lasting immunity
-
Improvement in antigen presentation.
- Sequestration and slow release of vaccine antigens (long-lasting antigenic
stimulation).
Presentation
of the vaccinal antigens in relation to
their adjuvants allows for a strong immune
response to Mycoplasma hyopneumoniae. |
2.
Levamisole: strong humoral and cellular response
- Induction of an enhanced antibody response.
- Increase in chemo-attraction of antigen-presenting
cells.
- Enhancement of the immunologica memory of vaccinated pigs.
- Increase of the activity of neutrophilic granulocytes and macrophages.
- Enhancement of the number of T-limphocytes.
- Induction of the synthesis of nucleic acids and proteins in T-lymphocytes.
- Stimulation of Y-interferón production
|
A
highly immunogenic J strain |
-
J strain yields a more intense immune response
to Mh than standard vaccine strains.
- The vaccinal antigen consist of membrane proteins
together with virulence factors. |
A
stimulated humoral response
|
-
MYPRAVAC SUIS stimulates the production of
IgA, IgG and IgM, induces a local mucosal immune
response in the respiratory tract, and neutralises M.
hyopneumoniae.
The
most important type of antibody is
IgA, wich acts locally at the mucosal
surface to neutralise the mycoplasma
organism. |
|
An
increased cellular response
|
| -
MYPRAVAC SUIS enhances macrophages and T-lymphocyte
function, stimulates interferon-y and
increases plasma cell (B-lymphocyte) levels,
which produce effective antibodies. |
Excellent
syringeability
|
| -
MYPRAVAC SUIS is very syringeable and makes
handling eaiser. |
Absence
of reactions at the injection site
|
-
MYPRAVAC SUIS exhibits local and systemic
innocuousness and does not produce reactions
at the injection site.. |
|
